VNRX (volition.com) Net earnings per share (EPS TTM)

The integration of Nu.Q into standard blood tests is driving the growth of VolitionRx Limited (VNRX) average annual revenue per user. While the high precision of epigenetic screening strengthens brand authority, R&D expenditures and a slow time-to-market for tests are creating financial pressure. This chart illustrates the profit response to business scaling, while -3.03 captures the current value of the indicator.

VNRX volition.com Earnings per share for the last twelve months (07/04/2022 - 11/15/2026)

Metric breakdowns and analytics for VolitionRx Ltd (VNRX)

- current quotes and average value forecast:

Price Chart VolitionRx Ltd.|VNRX - Broker Consensus Forecast

- business market valuation indicators:

Market Capitalization VolitionRx Ltd.|VNRX - Enterprise Value

- business book valuation details:

Net Assets per Single Share VolitionRx|VNRX - Company Book Value|Market Cap to Net Assets Ratio volition.com|VNRX - Company Assets

- debt level and financial liquidity data:

- earnings and multiples data:

VNRX - Company Net Income|Expected Profit VolitionRx Limited|VNRX - Price to Earnings Ratio|Forward P/E Multiple VolitionRx Ltd.|VNRX - Growth-Adjusted Market Cap to Net Income|Enterprise Value to EBITDA Ratio VolitionRx Limited|VNRX - Company profit before taxes, interest and amortization|Net earnings per share (EPS TTM) VolitionRx|VNRX - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months volition.com|VNRX - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year VolitionRx Limited

- sales and revenue indicators:

VNRX - Company Sales Volume|Company Projected Revenue VolitionRx|VNRX - Market Capitalization-to-Revenue Ratio|Forward Price-to-Revenue Multiple VolitionRx|VNRX - Sales Growth YoY (Last 12 Months)

Fundamental company analysis:VNRX - VolitionRx Limited

Mass-produced product of VolitionRx Ltd.

This indicator determines the portion of net income attributable to a single common share over a rolling year. The metric allows for an assessment of real capital generation efficiency by excluding the impact of the total issuance volume. For VolitionRx Limited (VNRX), the development of this figure depends directly on the commercialization of oncology tests and the hiring of US market experts. By analyzing the rolling 12-month net income per share, an investor can see the pace of business scaling. Steady growth of the line confirms the transition from scientific research to a profitable operating model.

Competitors of VolitionRx Limited